



VIA EMAIL: AGO.highcostprescriptiondrugs@vermont.gov

October 20, 2021

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

RE: Notice of a New Prescription Drug Pursuant to 18 V.S.A. § 4637(b)

To Whom It May Concern:

Pursuant to 18 V.S.A. § 4637(b), ChemoCentryx, Inc. hereby notifies the Attorney General of Vermont of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program. The new product that has been launched, in two distinct package sizes, is:

NDC Number	Product Name	Dosage Form	Strength	Package Size	Date of Market Entry
73556-0168-01	TAVNEOS™ (avacopan)	Oral capsules	10mg	180 EA	October 18, 2021
73556-0168-02	TAVNEOS™ (avacopan)	Oral capsules	10mg	30 EA	October 18, 2021

Sincerely,

DocuSigned by:

DF083D08F3C941B...
Lucia Bonnemaison

Market Access Analytics and Contracting Director
ChemoCentryx, Inc.